At present, ApoC1 is the only known endogenous inhibitor of cholesteryl ester transfer protein [10], and this constitutive action of apoC1 is impaired in coronary artery disease of dyslipidemic patients [11]. Here, APOC1 is linked to coronary artery disorder.